Study of REM-422 in Patients With AML or Higher Risk MDS
Study of REM-422 in Patients With AML or Higher Risk MDS
Recruiting · NCT06297941 · Registry updated 2025-04-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of REM-422 in Patients With AML or Higher Risk MDS | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2025-04-23 | NCT06297941 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Remix Therapeutics | 2 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| AP-HP - Hôpital Saint-Louis | Paris | France | 1 |
| Centre Hospitalier Universitaire (CHU) de Bordeaux | Bordeaux | France | 1 |
| City of Hope | Duarte | United States | 238 |
| Institut de Cancerologie Gustave-Roussy | Villejuif | France | 2 |
| IUCT-Oncopole | Toulouse | France | 3 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Memorial Sloan Kettering | New York | United States | 27 |
| Moffitt Cancer Center | Tampa | United States | 523 |